Evidence map›Paper›PMID 38932409›Full record

ArticleVaccines2024

Evaluation of Formalin-Inactivated Vaccine Efficacy against Red Seabream Iridovirus (RSIV) in Laboratory and Field Conditions.

Joon-Gyu Min, Guk-Hyun Kim, Chong-Han Kim, Woo-Ju Kwon, Hyun-Do Jeong, Kwang-Il Kim

Abstract read
In one paragraph

Article in Vaccines, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Joon-Gyu MinDepartment of Aquatic Life Medicine, Pukyong National University, Busan 48513, Republic of Korea.ORCID 0000-0001-6018-9747
Guk-Hyun KimDepartment of Aquatic Life Medicine, Pukyong National University, Busan 48513, Republic of Korea.
Chong-Han KimVaccine Research Institute, Woogene B&G Co., Ltd., Seoul 07299, Republic of Korea.ORCID 0009-0007-4048-9030
Woo-Ju KwonVaccine Research Institute, Woogene B&G Co., Ltd., Seoul 07299, Republic of Korea.ORCID 0000-0002-3756-5094
Hyun-Do JeongDepartment of Aquatic Life Medicine, Pukyong National University, Busan 48513, Republic of Korea.
Kwang-Il KimDepartment of Aquatic Life Medicine, Pukyong National University, Busan 48513, Republic of Korea.ORCID 0000-0001-7003-5696

Funding

Korea Institute of Marine Science and Technology Promotion 00236096
6 · The paper itself

Abstract

Red seabream iridovirus (RSIV) is a major cause of marine fish mortality in Korea, with no effective vaccine available since its first occurrence in the 1990s. This study evaluated the efficacy of a formalin-killed vaccine against RSIV in rock bream under laboratory and field conditions. For the field trial, a total of 103,200 rock bream from two commercial marine cage-cultured farms in Southern Korea were vaccinated. Farm A vaccinated 31,100 fish in July 2020 and monitored them for 18 weeks, while farm B vaccinated 30,700 fish in August 2020 and monitored them for 12 weeks. At farm A, where there was no RSIV infection, the vaccine efficacy was assessed in the lab, showing a relative percentage of survival (RPS) ranging from 40% to 80%. At farm B, where natural RSIV infections occurred, cumulative mortality rates were 36.43% in the vaccinated group and 80.32% in the control group, resulting in an RPS of 54.67%. The RSIV-infectious status and neutralizing antibody titers in serum mirrored the cumulative mortality results. This study demonstrates that the formalin-killed vaccine effectively prevents RSIV in cage-cultured rock bream under both laboratory and field conditions.

Indexed as

field trialformalin-inactivated vaccinerock breamRSIVvaccine

Identifiers

PMID38932409
PMCPMC11209460

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.